Bicycle Therapeutics to Present Key Data on Zelenectide Pevedotin at 2024 SABCS

Bicycle Therapeutics plc (NASDAQ: BCYC), a leader in the development of a new class of therapeutics based on bicyclic peptide technology, will present significant data at the 2024 San Antonio Breast Cancer Symposium (SABCS) from December 10-13. The company will showcase findings on the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in triple-negative breast cancer (TNBC) patients with NECTIN4 gene amplification.

In addition to the SABCS presentation, Bicycle Therapeutics will unveil topline data on the combination of zelenectide pevedotin with pembrolizumab in first-line metastatic urothelial cancer patients who are ineligible for cisplatin treatment. Moreover, the company will reveal monotherapy results for zelenectide pevedotin in non-small cell lung cancer patients exhibiting NECTIN4 gene amplification.

A poster presentation, titled "Enhanced anti-tumor activity of zelenectide pevedotin in triple negative breast cancer patients with NECTIN4 gene amplification," will be held on Thursday, December 12, from 5:30-7 p.m. CT. The lead author of the study is Dr. Niklas Klümper from University Hospital Bonn.

To discuss these findings, Bicycle Therapeutics will host a conference call and webcast on Friday, December 13, at 7 a.m. CT. Interested parties can join the call by dialing +1-833-816-1408 (U.S.) or +1-412-317-0501 (international) and requesting the Bicycle Therapeutics call. A live webcast and replay will be available on the company's website.

Bicycle Therapeutics, headquartered in Cambridge, UK, is focused on developing Bicycle® molecules, which are fully synthetic peptides that offer high affinity and selectivity for target binding. The company is advancing several clinical programs, including zelenectide pevedotin, a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, and other innovative therapies across oncology and beyond.